EGFR and neoplasm: The conjugation of anti-EGFR antibodies to the LNPs enhanced both the delivery of the siRNA and its anti-tumor effects, leading to a 50% greater reduction in tumor volume compared to control treatments (LNPs, which are coated with isotype control antibodies), with superior suppression of HPV oncogenes and increased apoptosis in both in vitro and in vivo models [124].